A Dedicated Low-Cost Fluorescence Microfluidic Device Reader for Point-of-Care Ocular Diagnostics
暂无分享,去创建一个
Mark Niedre | Shashi K. Murthy | David I. Walsh | Glenn J. Jaffe | Noah Pestana | Paul Hahn | Adam Hatch
[1] Quan Dong Nguyen,et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. , 2009, Ophthalmology.
[2] A. Schachat,et al. A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.
[3] S Sivaprasad,et al. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature , 2010, Eye.
[4] Vincent Linder,et al. Microfluidics at the crossroad with point-of-care diagnostics. , 2007, The Analyst.
[5] J. Caminal,et al. INTRAVITREAL INFLIXIMAB IN PATIENTS WITH MACULAR DEGENERATION WHO ARE NONRESPONDERS TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2010, Retina.
[6] R. Zengerle,et al. Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. , 2010, Chemical Society reviews.
[7] Matthias Bolz,et al. ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMAB , 2010, Retina.
[8] G. Whitesides. The origins and the future of microfluidics , 2006, Nature.
[9] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[10] J. Tombran-Tink,et al. PEDF in angiogenic eye diseases. , 2010, Current molecular medicine.
[11] P. Yager,et al. Point-of-care diagnostics for global health. , 2008, Annual review of biomedical engineering.
[12] James V. Green,et al. Microfluidic pillar array sandwich immunofluorescence assay for ocular diagnostics , 2011, Biomedical microdevices.
[13] M. Weger,et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab , 2009, Eye.
[14] J. Vander,et al. Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes , 2011 .